Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Pharmaron Beijing Co's Net Income for the
three
months ended in Jun. 2026 was $61 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was $246 Mil.
Pharmaron Beijing Co (OTCPK:PHBBF) Net Income Explanation
Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
Pharmaron Beijing Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable business
Consistent accounting methods
And few restructurings
The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Pharmaron Beijing Co Net Income Related Terms
Pharmaron Beijing Co Net Income Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Net Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
Net Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $246 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (PHBBF) has a Net Income of $246 Mil as of Jun. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Net Income too high?
Pharmaron Beijing Co's current Net Income is $246 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Net Income compare to VRTX and REGN?
Pharmaron Beijing Co's Net Income of $246 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Net Income is $246 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Net Income of $246 Mil. The stock's GF Value™ is $1.35, compared to a current price of $1.93 — trading 43% above its estimated fair value. The current Net Income is $246 Mil. Pharmaron Beijing Co's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Net Income is $246 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 43% above its estimated GF Value™ of $1.35.
Key valuation signals for PHBBF:
Net Income: $246 Mil
GF Value™: $1.35 vs. price of $1.93 (43% above fair value)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
81GF Score
Get the complete analysis for PHBBF
Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
